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Abstract
P-glycoprotein (Pgp) and multidrug resistance-associated proteins (MRPs) are ATP-dependent transporters involved in efflux
of toxins and xenobiotics from cells. When overexpressed, these transporters can mediate multidrug resistance (MDR) in
mammalian cells, and changes in Pgp expression and sequence are associated with drug resistance in helminths. In addition
to the role they play in drug efflux, MDR transporters are essential components of normal cellular physiology, and targeting
them may prove a useful strategy for development of new therapeutics or of compounds that enhance the efficacy of
current anthelmintics. We previously showed that expression of Schistosoma mansoni MDR transporters increases in
response to praziquantel (PZQ), the current drug of choice against schistosomiasis, and that reduced PZQ sensitivity
correlates with higher levels of these parasite transporters. We have also shown that PZQ inhibits transport by SMDR2, a Pgp
orthologue from S. mansoni, and that PZQ is a likely substrate of SMDR2. Here, we examine the physiological roles of SMDR2
and SmMRP1 (the S. mansoni orthologue of MRP1) in S. mansoni adults, using RNAi to knock down expression, and
pharmacological agents to inhibit transporter function. We find that both types of treatments disrupt parasite egg
deposition by worms in culture. Furthermore, administration of different MDR inhibitors to S. mansoni-infected mice results
in a reduction in egg burden in host liver. These schistosome MDR transporters therefore appear to play essential roles in
parasite egg production, and can be targeted genetically and pharmacologically. Since eggs are responsible for the major
pathophysiological consequences of schistosomiasis, and since they are also the agents for transmission of the disease,
these results suggest a potential strategy for reducing disease pathology and spread.
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Introduction
Schistosomiasis is a major endemic disease that affects hundreds
of millions worldwide, causes nearly 300,000 deaths annually, and
has an estimated human health burden on a par with malaria or
tuberculosis [1–3]. The causative agents of schistosomiasis are
parasitic flatworms of the genus Schistosoma. Adult schistosomes
reside in the vasculature of the host, where they take up nutrients
and deposit eggs which evoke a host immunopathological response
that is responsible for the development of the pathophysiological
effects of chronic schistosomiasis. Like other organisms, schisto-
somes must eliminate toxic metabolites and xenobiotics, and, as
parasites, must in addition deal with potentially toxic compounds
generated by the host [4].
Multidrug resistance (MDR) proteins are cellular efflux
transporters with broad substrate specificities that likely play
essential roles in this process, as well as in other significant aspects
of parasite physiology. Several of these transporters are members
of the ATP binding cassette (ABC) superfamily of proteins,
including P-glycoprotein (Pgp), multidrug resistance-associated
proteins (MRPs), breast cancer resistance protein (BCRP), and
others [5,6]. Their major role in normal cellular physiology is to
remove or exclude xenobiotics and metabolic toxins, but they are
also involved in a wide array of physiological functions [7–9],
including regulation of cell death [10] and immune function [11].
As their name suggests, MDR transporters also mediate
multidrug resistance, a phenomenon in which cells that develop
resistance to a particular drug also show unexpected cross-
resistance to several structurally unrelated compounds. Though
MDR transporter-mediated multidrug resistance was described
originally in mammalian cells [12], MDR transporter expression
levels and allele frequencies are also altered in anthelmintic-
resistant populations of helminths, including schistosomes [13–22].
The role these transporters might be playing in helminth and other
parasite drug resistance has recently been reviewed [23–27].
Praziquantel (PZQ) is the current drug of choice against
schistosomiasis. It is highly effective against all schistosome species,
and shows minimal adverse effects [28–30]. However, schisto-
somes show stage- and sex-dependent differences in susceptibility
to PZQ [31–33], and the mode of action of the drug remains
unresolved three decades following its introduction [34,35].
Though currently there is little compelling evidence that PZQ
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of worm isolates exhibiting reduced PZQ susceptibility following
drug pressure have appeared in the literature, and could be
harbingers of the emergence of more widespread resistance [36–
38]. Recent studies on changes in gene expression in response to
PZQ may provide clues to the mode of action of the drug and to
possible molecular mechanisms underlying development of
resistance [39,40].
ABC transporter cDNAs that have been characterized in
schistosomes include SMDR2 [41], a S. mansoni orthologue of Pgp,
and SmMRP1 [42], a S. mansoni orthologue of MRP1. SMDR2
RNA is expressed at higher levels in female parasites than in males
[21,41], while males express higher SmMRP1 RNA levels than
females [42]. Notably, S. mansoni adults upregulate expression of
both of these transporters in response to PZQ [21,42].
Furthermore, higher basal levels of both SMDR2 and SmMRP1
correlate with reduced PZQ susceptibility [21,42], and PZQ
inhibits, and is also a likely substrate of, SMDR2 [43]. Based on
these findings, we have hypothesized that schistosome MDR
transporters may be modulating the responsiveness of parasites to
PZQ [44]. We also predict that schistosome multidrug transporters
play critical roles in worm physiology, development, and perhaps
in modifying host responses.
In this report, we use genetic and pharmacological approaches
to examine the effects on schistosomes of interference with normal
MDR transporter function. We find that knockdown of SMDR2
or SmMRP1 expression in adult worms, or exposure of parasites
to pharmacological inhibitors of these transporters, disrupts egg
production in S. mansoni cultured ex vivo. Furthermore, adminis-
tration of any of four structurally diverse Pgp inhibitors to
schistosome–infected mice results in a reduced egg burden in the
livers of those infected mice. Schistosome eggs are associated with
the majority of morbidity in chronic schistosomiasis, and are the
agents of disease transmission. Our findings indicate that MDR
transporters may be essential components of pathways involved in
schistosome reproduction, and may serve as highly ‘‘drugable’’
targets for new antischistosomals that decrease egg-dependent
pathology and could serve to reduce disease transmission.
Results
Knockdown of SMDR2 and SmMRP1 RNA and protein in
S. mansoni adults
We used electroporation of SMDR2 and SmMRP1 siRNAs to
knock down expression of the multidrug resistance proteins SMDR2
and SmMRP1inadult worms.Asshown inFig. 1, electroporation of
adult parasiteswith siRNA targeted againsteither sequenceresults in
substantial reduction of the relative expression level of that gene,
both at the RNA and protein levels. Levels of RNA expression for
both genes in pooled adult schistosomes are reduced by 50–70%
compared to controls. Addition of SmMRP1 siRNA to the SMDR2
siRNA does not appear to affect RNA levels of SMDR2, nor does
addition of SMDR2 siRNA appear to additionally decrease levels of
SmMRP1 RNA. Protein expression, as measured by immunoblot-
ting with anti-Pgp and anti-MRP1 antibodies, is also reduced.
Knockdown of SMDR2 or SmMRP1 decreases egg
production in S. mansoni adults
Adult schistosomes perfused from the murine host and
maintained in vitro will continue to produce eggs, though only
those deposited during the first 48 h following perfusion from the
host appear to be viable [45]. We compared the cumulative
number of eggs produced by worms over a 2–3-day span following
electroporation with siRNA against SMDR2 or SmMRP1 (or
both). We also counted eggs produced by control worms
electroporated with luciferase siRNA or with no treatment. As
shown in Fig. 2, knockdown of either MDR transporter gene (or
both) resulted in a significant reduction in cumulative egg
production compared to controls.
Exposure of adult S. mansoni to MDR inhibitors disrupts
egg production
As shown above, knockdown of MDR transporter expression in
adult S. mansoni results in decreased parasite egg production.
Previous work described in a patent [46] showed that exposure of
worms to verapamil, a mammalian L-type voltage-gated Ca
2+
(Cav) channel blocker and also an inhibitor of SMDR2 [43] and
mammalian Pgp [47,48], reduces egg production. We have
confirmed these results for verapamil, finding no eggs whatsoever
following incubation of adults in 10 mM verapamil for 2 days.
Based on these results, we examined other structurally diverse
Pgp and MRP1 inhibitors for their effects on S. mansoni egg
production. Drugs tested included: the immunosuppressant
cyclosporin A (CSA), which is also an inhibitor of mammalian
Pgp; R(+)-verapamil (dexverapamil), an enantiomer of verapamil
which is significantly less active than the S(2) enantiomer against
Cav channels, but which retains potent and selective competitive
inhibitory activity against Pgp [49]; C-4, a curcumin derivative
that is a cell-permeable, reversible Pgp inhibitor [50]; tariquidar
(aka XR9576), a third-generation, selective and highly potent Pgp
inhibitor [51–53] (which also appears to be a substrate of BCRP at
low concentrations and an inhibitor of BCRP at .100 nM
concentrations [54]); and MK 571, a potent inhibitor of MRP1
[55]. As shown in Fig. 3, exposure of adult worms to any of these
compounds ex vivo resulted in a dramatic, dose-dependent
reduction in cumulative parasite egg production over two
(tariquidar, MK 571) or five (CSA, dexverapamil, C-4) days in
culture. Specifically, exposure of worms to CSA (Fig. 3A) results in
a ,75% decrease in egg production at concentrations of 1 mM–
22.5 mM. Worms exposed to C-4 (Fig. 3B) show a 62% decrease at
10 mM and a 92% decrease at 25 mM concentrations, while
dexverapamil (Fig. 3C) produces a ,65% decrease at 1–2 mM.
Author Summary
Schistosomes are parasitic flatworms that are the causative
agents of schistosomiasis, a major tropical disease. As
adults, schistosomes reside within the host vasculature,
taking up nutrients, evading host defenses, and expelling
wastes and toxins. Multidrug resistance transporters are
involved in removal of toxins and foreign compounds,
including drugs, from cells. These transporters have broad
selectivity, and when upregulated or mutated, can confer
resistance to a wide spectrum of drugs against mammalian
tumor cells. They are also associated with drug resistance
in various parasites, including helminths. In this report, we
have used knockdown of expression of these proteins and
pharmacological inhibition of their transport function to
dissect their physiological role in the schistosome life
cycle. We find that either reducing transporter expression
or pharmacologically inhibiting transporter function leads
to disruption of egg production by adult worms. Eggs
deposited within the host are the major cause of disease
pathology, and eggs excreted by the host are the means of
continuation of the life cycle and transmission of the
disease. The capability to interfere with schistosome egg
production could have major implications for develop-
ment of new treatment strategies.
Function of Schistosome MDR Transporters
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results in no eggs being deposited whatsoever (Fig. 3D), and in
apparent worm lethality (absence of movement or response to
stimuli) after 72 h exposure (data not shown). The MRP1 inhibitor
MK 571 also disrupts egg production, with no eggs deposited
following exposure to 50 mM MK 571 (Fig. 3E). Disruption of egg
production also occurs when females cultured alone are exposed to
Pgp inhibitors (Fig. 3F). Drug-treated females could not be rescued
by addition of untreated males; egg production was still inhibited
(data not shown), indicating that the process being targeted is likely
autonomous to the female worms or the eggs themselves. Drug
treatment, exemplified by dexverapamil, appears to affect the
morphology of female reproductive organs (Fig. S1).
Those eggs that were deposited by worms treated with MDR
inhibitors such as tariquidar were often morphologically abnormal
(Fig. 4), appearing malformed, necrotic, and sometimes disintegrat-
ed or in the process of fragmentation. However, other than C-4, the
Pgp inhibitors do not appear to be acting on the eggs themselves.
Thus, eggs isolated from infected mouse livers and subsequently
exposed to CSA, dexverapamil, or tariquidar hatch normally (data
not shown). Eggs exposed to C-4 do not appear to hatch.
Administration of Pgp inhibitors to S. mansoni-infected
mice decreases liver egg burden
To test whether MDR inhibitors would also disrupt egg
production by parasites within the murine host, we administered
three intraperitoneal doses (100 ml volume each) of either CSA
(60 mg/kg), C-4 (50 mg/kg), dexverapamil (60 mg/kg), or tariqui-
dar (15 mg/kg) to S. mansoni-infected mice at 5–6 weeks post-
infection. Livers of infected mice treated with any of the four Pgp
inhibitors showed significantly reduced egg burden compared to the
vehicle-injected control (Fig. 5A). Egg burden was reduced
approximately 80% following administration of C-4, 65% following
administration of dexverapamil, 55% following administration of
tariquidar, and 50% following administration of CSA. These
changes were reflected in significant reductions in the number of
liver granulomas found in drug-treated and control mice, except in
the case of CSA, which showed no difference from control (Fig. 5B).
The largest reduction in granuloma number per cm
2 (45%) was
found for dexverapamil. We also observed a significant reduction in
granulomasizewheninfected mice weretreatedwith anyofthe four
Pgp inhibitors (Table 1). To determine whether the effects of these
drugs on parasite egg production persist outside of the host, we
perfused adult worms from C-4-, dexverapamil-, and CSA-treated
mice and measured subsequent egg production during culture ex
vivo. These cultured adult worms do not show a significant decrease
in egg production, except for those parasites perfused from mice
that had been treated with CSA (Fig. 5C).
Discussion
In this report, we used genetic and pharmacological approaches
to disrupt normal MDR transporter function in S. mansoni.
Figure 1. Knockdown of SMDR2 and SmMRP1 expression in adult parasites. Adult parasites were perfused at 6–7 weeks post infection and
electroporated with 3 mg of siRNAs or water. Following electroporation, pooled adult worms (males and females) were incubated as described in
Materials and Methods, and the expression of SMDR2 and SmMRP1 analyzed for changes in RNA and protein abundance (A, B). Western blot analysis
of anti-Pgp (A) or anti-MRP1 (B) cross-reactive proteins (upper panel) isolated from worms treated with SMDR2 siRNA (A, lane 2), SmMRP1 siRNA (B,
lane 2), or water (Control, lane 1). Note the decrease in immunoreactivity for both target sequences. Anti-b-tubulin was used as a loading control. (C,
D) Relative expression of SMDR2 (n=6–7) or SmMRP1 (n=3–4) RNA in adult worms treated with water (H2O, white bars), luciferase siRNA (grey bars),
SMDR2 siRNA or SmMRP1 siRNA (black bars), or both SMDR2 and SmMRP1 (hatched bars). SMDR2 and SmMRP1 siRNAs efficiently knock down the
mRNA expression levels of SMDR2 by $50% and SmMRP1 by $70%, respectively. The fold changes were determined by quantitative RT-PCR using
18S RNA as the reference gene. *, ** indicate P,0.05 and P,0.01, respectively, compared to the water control, ANOVA.
doi:10.1371/journal.pntd.0001425.g001
Function of Schistosome MDR Transporters
www.plosntds.org 3 December 2011 | Volume 5 | Issue 12 | e1425Strikingly, both approaches produced quite similar phenotypes.
Knockdown in adult schistosomes of SMDR2, SmMRP1, or both
resulted in a marked reduction in parasite egg production ex vivo,a s
did exposure of adult worms to the different MDR inhibitors.
Notably, schistosomes residing within the murine host were also
apparently susceptible to disruption of MDR function. S. mansoni-
infected mice treated with any of four different Pgp inhibitors,
including the potent third-generation inhibitor tariquidar, showed
significant reductions in parasite egg burden in their livers. These
results point to an essential role for ABC-type MDR transporters
in schistosome reproduction.
Previous studies by us and others have investigated the
involvement of these transporters in PZQ action and susceptibility.
For example, we showed that PZQ interacts directly with the S.
mansoni Pgp orthologue SMDR2, acting to both inhibit substrate
transport, and as a likely substrate itself [43]. Furthermore, both
SMDR2 and SmMRP1 are upregulated in response to PZQ and
higher expression of these transporters is associated with reduced
PZQ susceptibility [21,42]. Here, however, we show that SMDR2
and SmMRP1 additionally appear to play important roles in
schistosome reproductive physiology.
Though the MDR inhibitors we used in these experiments are
structurally diverse and have wholly different molecular targets and
modes of action, one characteristic they share is that they all inhibit
mammalian Pgp or MRP1. CSA has previously been shown to have
schistosomicidal activity at higher concentrations, most potently
during the early course of infection [56]. This activity appears to be
independent of the drug’s immunosuppressive properties [56,57],
and the precise mode of the drug’s antischistosomal action remains
largely undefined [58]. CSA has also been shown to ‘‘sterilize’’
worms when administered every day over an eight-day period to S.
mansoni-infected mice (days 28–35 post-infection), essentially
eliminating liver egg burden [59], a result comparable to ours.
CSA also enhances the pulmonary granuloma response in egg
injection assays [60], which appears to be consistent with the lack of
reduction we observe in the number of liver granulomas in CSA-
treated infected mice (Fig. 5B). Interestingly, CSA was the only drug
treatment in infected mice that appeared to have significant lasting
effects on schistosome egg production after parasites had been
removed from the CSA-treated host (Fig. 5C), perhaps indicating a
long-lived or irreversible effect on reproductive physiology.
A second drug we used, dexverapamil, is an enantiomer of
verapamil that is far less active against L-type Cav channels than
the active enantiomer, but which retains potent inhibitory activity
against mammalian Pgp. It too significantly disrupted egg
production. Interestingly, a racemic mixture of verapamil was
previously claimed in a patent to reduce egg production in S.
mansoni [46], and we have confirmed that finding. The reduction
in egg production following exposure of worms to dexverapamil,
along with our results showing that verapamil is a potent inhibitor
of SMDR2 [43], point to inhibition of S. mansoni Pgp, and not
disruption of Cav channel function, as a likely mode of action.
C-4 is a derivative of curcumin that reverses the MDRphenotype
and that reversibly inhibits mammalian Pgp transport of rhodamine
[50]. Interestingly, curcumin, which also reverses MDR [61–63],
has been shown to have antischistosomal activity at high (50–
100 mM) concentrations and to reduce parasite egg production ex
vivoatlower(5–10 mM)concentrations [64].Tariquidaris one ofthe
third-generation Pgp inhibitors developed specifically for high
potency and selectivity against Pgp, and it completely eliminates S.
mansoni egg production ex vivo at concentrations $12.5 mM. Finally,
MK 571, an MRP1 inhibitor, also disrupts egg production.
Pairing of male and female worms is required for normal
development and maturation of female schistosomes (reviewed in
[65]). Thus, it is possible that the MDR inhibitors primarily affect
male worms, and indirectly affect egg production in females.
However, all of the Pgp inhibitors we tested decrease egg
production in female worms cultured in the absence of males
(Fig. 3F), and treated females are not ‘‘rescued’’ by addition of
untreated males to the culture. Thus, inhibition of egg production
does not appear to be due to effects of the drugs on male worms,
and pairing is not required for those effects to appear.
All four of the Pgp inhibitors we tested ex vivo reduce liver egg
burden in S. mansoni-infected mice. Use of other drug concentra-
tions or routes of administration may enhance this effect and
reduce pathology more dramatically. However, the fact that both
genetic (RNAi) and pharmacological interference with normal
MDR transporter function in schistosomes affects egg production
suggests a common mode of action underlying this outcome, and
that proper functioning of the parasite reproductive system may be
dependent on MDR transporter activity. Furthermore, since
excretion of eggs is essential for parasite transmission, and since
host responses to egg deposition represent the major source of
pathology in chronic schistosomiasis, disruption of egg production
by interference with MDR transporter function could signal a
vulnerability for exploitation in development of new antischisto-
somal therapeutics that exploit a multifaceted approach to reduce
morbidity and the spread of the disease [66]. Furthermore, since
higher levels of schistosome MDR transporters are associated with
reduced PZQ susceptibility [21,42], it will be interesting to
determine whether knockdown or inhibition of these transporters
potentiates the antischistosomal activity of PZQ.
Figure 2. Knockdown of SMDR2 or SmMRP1 in adult schisto-
somes disrupts parasite egg production. Adult schistosomes were
electroporated with H2Oo r3mg siRNAs and incubated in RPMI medium
for 48 h. Following electroporation, 2–3 adult pairs (n=4–7) were
cultured in 16-well plates for 4–5 days and the number of eggs
counted. RNAi treatments were luciferase siRNA (grey bar), SmMRP1
siRNA (black bar), SMDR2 siRNA (hatched bar), or both SmMRP1 and
SMDR2 siRNA (dotted bar). Egg counts within each experiment were
normalized to the corresponding worms treated with H2O (white bar).
Treatment with the MDR transporter siRNAs significantly reduced egg
production by $ 60%, but no significant change in egg production was
found for worms electroporated with luciferase siRNA or H2O.
*, *** indicate P,0.05 and P,0.001, respectively, ANOVA.
doi:10.1371/journal.pntd.0001425.g002
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Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the U.S. National Institutes of Health.
Animal handling and experimental procedures were undertaken in
compliance with the University of Pennsylvania’s Institutional
Animal Care and Use Committee (IACUC) guidelines (Animal
Welfare Assurance Number: A3079-01; IACUC protocol number
802105).
Reagents
C-4 [(E)-4-Chloro-N-(3-(3-(4-hydroxy-3-methoxyphenyl)acryloyl)
phenyl)benzamide] was from EMD Biosciences and cyclosporin A
was from Enzo Life Sciences. R(+)-verapamil HCl (dexverapamil)
and MK 571 were from Sigma-Aldrich. Tariquidar was from
MedKoo Biosciences. The mouse monoclonal antibodies against
Pgp (C219) and MRP1 (ab3371) were from Abcam. The anti-rabbit
tubulin antibody was from Santa Cruz Biotechnology (H-235).
Suppliers of molecular biology reagents are designated within the
text.
Figure 3. Exposure of S. mansoni adult worms in culture to MDR inhibitors disrupts egg production. Adult worm pairs (n=3–4) were
incubated in different concentrations of MDR inhibitors (black bars) for 48 h. Cumulative egg counts were normalized to those of control worms
(white bars), which were exposed to DMSO carrier. Addition of the Pgp inhibitors C-4 (A), dexverapamil (B), cyclosporin A (C), tariquidar (D), or the
MRP-1 inhibitor MK 571 (E) significantly disrupts egg production. (F) The effect of the Pgp inhibitors on egg production by females is independent of
presence of male worms. Adult females were incubated in the absence of males for 48 h in the culture media alone (Control), or in the presence of
10 mM cyclosporin A (CSA), tariquidar, dexverapamil, or C-4. Shown are the cumulative egg counts per female, n=3–5 for each treatment. *, **, and
*** indicate P,0.05, P,0.01, and P,0.001 respectively, ANOVA.
doi:10.1371/journal.pntd.0001425.g003
Function of Schistosome MDR Transporters
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Female Swiss Webster mice infected with S. mansoni (NMRI
strain) obtained from the NIAID Schistosomiasis Resource Center
at the Biomedical Research Institute in Rockville, MD were
perfused 6–7 weeks post-infection, as described [67]. Perfused
worms were maintained in RPMI (Invitrogen) plus 10% FBS
(Sigma), 1% penicillin/streptomycin, and 0.012% Timentin
(Plantmedia) at 37uC and 5% CO2.
RNA interference
Knockdown of RNAs encoding SMDR2 (NCBI Acc. #
L26287) or SmMRP1 (NCBI Acc. #GU967672) was as described
[68,69]. Briefly, following an overnight incubation in RPMI, adult
worms (5 males plus 5 females) were placed in a 0.4 cm
electroporation cuvette (USA Scientific Plastics) containing 50 ml
siPORT (Ambion) and 3 mg SMDR2 siRNA (IDT), SmMRP1
siRNA (IDT), or luciferase siRNA (Ambion). For electroporation,
a 20 ms square wave pulse of 125 volts was applied. The siRNAs
were designed using IDT SciTools RNAi Design and the target
sequences used in the studies were: SmMRP1 siRNA, 59-
GACCAATCAGCTAACCATAAATTTGTT- 39, which maps
to bp 3834–3860 of the SmMRP1 coding region RNA; and
SMDR2 siRNA, 59-TCGATCAAACCAACCAATCTCCTGT-
TT- 39, which maps to bp 2332-2358 of the SMDR2 coding
region RNA. The luciferase siRNA used for our control shows no
significant similarity to any sequences from the S. mansoni gene
database. Following electroporation, worms were incubated en masse
inRPMImediumfor2days.Theywerethensortedinto2–3 males/
female pairs per well in a 12-well plate, in which they were
maintained for an additional 48 to 72h, and subsequently removed
from the medium, quick-frozen in liquid nitrogen, and stored at
280uC until further use. The number of eggs deposited in each well
by these worms over this 48 to 72 h period was counted (see below).
RNA and protein extractions
Total RNA was extracted as described [42], using either
RNAqueous-4-PCR (Ambion) or NucleoSpin RNA XS (Ma-
cherey-Nagel), and subsequently treated with Turbo-DNAase
(Ambion) or rDNAase (Macherey-Nagel) according to the manu-
facturer’s instructions. For protein extractions, worms were
homogenized in cell disruption buffer (Ambion Paris Kit) with a
cocktail of protease inhibitors (Sigma) at 4uC and incubated for
Figure 4. Eggs produced by worms exposed to MDR inhibitors show morphological abnormalities. Micrographs of S. mansoni eggs
collected from adult worm pairs cultured in the absence (A) or presence (B) of tariquidar for 48 h. Control eggs appear normal and oval shaped with a
lateral spine, in contrast to malformed, necrotic, and disintegrated eggs from worms exposed to tariquidar.
doi:10.1371/journal.pntd.0001425.g004
Figure 5. Administration of MDR inhibitors to S. mansoni-infected mice reduces host liver egg burden. (A). Mean egg burden/g of liver
(n=3–5) from mice at 6–7 weeks post infection with approximately 200 cercariae, normalized to Control within each experiment. Mice were treated
with 3 doses on alternating days of: diluted DMSO/Cremophore EL carrier (Control; white bar, n=8); C-4 (50 mg/kg, n=6); tariquidar (15 mg/kg,
n=3); dexverapamil (60 mg/kg, n=3), or cyclosporin A (CSA, 60 mg/kg, n=6). (B) Granulomas/cm
2 found in livers of infected mice (n=6) treated
with carrier or drugs, as in A. (C) Mean ex vivo egg production (n=4–6) from 3 pairs of adult parasites perfused from mice that were treated with the
MDR inhibitors dexverapamil (60 mg/kg), C-4 (50 mg/kg), or cyclosporin A (CSA; 60 mg/kg) and subsequently cultured in RPMI for 48 h. Control
represents eggs from parasites perfused from mice treated with carrier alone (diluted DMSO/Cremophore EL). Only CSA continues to disrupt egg
production through the culture period. *, **, ***, and **** indicate P,0.05, P,0.01, P,0.001, and P,0.0001, respectively, unpaired, two-tailed t-tests.
doi:10.1371/journal.pntd.0001425.g005
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at 4uC and the supernatant collected was used immediately or
stored at220uC. Totalprotein concentrations weremeasuredusing
a Bradford assay (Fermentas) with BSA (Sigma) as a standard.
Real-time RT-PCR
Real-time RT-PCR was used to measure RNAi knockdown. It
was performed using the Brilliant II SYBR green qRT-PCR Master
kit (Stratagene) on an Applied Biosystems 3500 according to the
manufacturer’s recommendations. Primers used for the amplifica-
tion of SMDR2, SmMRP1 and 18S ribosomal RNA have been
described previously [21,42]. Data were analyzed using the 2
2DDCt
method [70] to determine the relative expression ratio between
target (SmMRP1, SMDR2) and reference genes (18S RNA).
Immunoblotting
Knockdown was also measured at the protein level by
immunoblotting. Protein samples (25 mg) were electrophoresed
on Bis-Tris gels in MOPS running buffer (Invitrogen), blotted, and
probed with anti-Pgp, anti-MRP, or anti-b-tubulin antibodies, as
described [21,42].
Treatment of worms with pharmacological compounds
Drugs were dissolved in dimethyl sulfoxide or ethanol for stock
solutions, which were subsequently diluted 1:1 into Cremophor-EL
(Sigma), and finally to an appropriate concentration in culture
media. For in vitro treatments, 2 or 3 adult worm pairs were
incubated in our standard media with different concentrations of
drug (or carrier for controls) for two days. For treatments of S.
mansoni-infected mice, drugs dissolved in 1:1 DMSO/Cremophore-
EL (or carrier alone for controls) were diluted to 100 or 200 mli n
PBS and administered intraperitoneally to mice beginning at 5–6
weeks post infection with approximately 200 cercariae. Each
infected mouse was treated once per day on three alternate days
with R(+)-verapamil (dexverapamil) HCl (60 mg/kg), C-4 (50 mg/
kg), tariquidar (15 mg/kg) or cyclosporin A (60 mg/kg).
Egg counts ex vivo
Worms subjected to different treatments were placed in individual
wells of a multiwell plate, with 2–4 worm pairs (male + female) per
well, and maintained in our standard worm culture medium at 37uC
and 5% CO2. As reported by others [45,71], adult worms perfused
from mice will produce eggs while cultured ex vivo.A tv a r i o u st i m e s
(typically 2d or 5d), we counted the cumulative number of eggs
produced from treated and control worms, using a dissecting
microscope. The number of eggs per control females typically ranged
from 20 to 100, and varied within that range between different
batches of perfused worms. For that reason, for all experiments
except those in Fig. 3F, worm counts within each experiment were
normalized to the mean value for the control worms for that
experiment. The state of pairing of males and females was dynamic
over the course of the incubation; paired worms would often separate,
and these separated worms would often become paired again, In
addition to obtaining egg counts, abnormal morphology of eggs was
also noted and photographed. Adult schistosomes were fixed, stained
with hydrochloric carmine (Sigma), and examined on a Leica SP5
two-photon confocal microscope, as described [72,73].
Enumeration of egg burden in mouse livers
Approximately 24 h following drug treatment, and while
simultaneously collecting adult schistosomes, livers from drug-
treated and control mice were isolated and weighed. A 0.25–0.5 g
portion from the equivalent lobe of liver from different treatment
conditions was dissected and incubated in 4% KOH for 16 to 24 h
at 37uC as described [67]. The suspensions were examined for S.
mansoni eggs, which were sampled and counted under a dissecting
microscope multiple times for each mouse, and the number of eggs
per gram of liver calculated. In some experiments, egg numbers
were also corrected for the number of females perfused from each
mouse, though that value did not vary significantly between the
different treatments. In order to correct for variation between
experiments, average egg counts per gram of liver within each
experiment were normalized, with the mean control value set as 1.
Remaining liver tissue was formalin-fixed, paraffin-embedded, and
stained with haematoxylin and eosin. Granulomas within a set
area of the sections were counted and the number of granulomas
per cm
2 calculated. To calculate granuloma area, the diameter of
those granulomas surrounding a single egg from each section were
measured using QCapture Pro software. Granulomas were
assumed to be a spherical shape [74] and sizes calculated from
the different fields of the histopathological sections.
Statistics
Data are expressed as mean 6 SEM, and were tested for
statistical significance using either ANOVA or unpaired t-tests, as
noted in the figure legends.
Supporting Information
Figure S1 Dexverapamil exposure alters the morphol-
ogy of the female reproductive system. Confocal micro-
graph of untreated (A) and 10 mM dexverapamil-treated (B) female
S. mansoni. Following a 48 h incubation, worms were carmine-
stained and examined by laser-scanning confocal microscopy as
described [72,73]. Arrows indicate cluster of developing, immature
oocytes in control (A) vs. the second cluster of apparently mature
oocytes in the dexverapamil-treated worms (B). Scale bar is 25 mm.
(TIF)
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Table 1. Mean granuloma area (mm
2 6 s.e.m) in livers from S.
mansoni-infected mice treated with Pgp inhibitors.
Control C-4 Dexverapamil CSA Tariquidar
(n=31) (n=33) (n=24) (n=34) (n=29)
3593 6 381.4 2670 6 287.8
* 1562 6 177.7
*** 2313 6 287.8
** 2525 6 236.1
*
*, **, and *** indicate P,0.05, P,0.01, and P,0.001, respectively, compared to
Control, ANOVA. n = number of granulomas measured.
doi:10.1371/journal.pntd.0001425.t001
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